0001209191-20-054677.txt : 20201013
0001209191-20-054677.hdr.sgml : 20201013
20201013171055
ACCESSION NUMBER: 0001209191-20-054677
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201009
FILED AS OF DATE: 20201013
DATE AS OF CHANGE: 20201013
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pasquale Maria E
CENTRAL INDEX KEY: 0001736295
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-12400
FILM NUMBER: 201237308
MAIL ADDRESS:
STREET 1: C/O INCYTE CORPORATION
STREET 2: 1801 AUGUSTINE CUT-OFF
CITY: WILMINGTON
STATE: DE
ZIP: 19803
FORMER NAME:
FORMER CONFORMED NAME: Pasquale Maria P
DATE OF NAME CHANGE: 20180402
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INCYTE CORP
CENTRAL INDEX KEY: 0000879169
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 943136539
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1801 AUGUSTINE CUT-OFF
CITY: WILMINGTON
STATE: DE
ZIP: 19803
BUSINESS PHONE: 3024986700
MAIL ADDRESS:
STREET 1: 1801 AUGUSTINE CUT-OFF
CITY: WILMINGTON
STATE: DE
ZIP: 19803
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE CORP
DATE OF NAME CHANGE: 20030318
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE GENOMICS INC
DATE OF NAME CHANGE: 20000710
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930902
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-10-09
0
0000879169
INCYTE CORP
INCY
0001736295
Pasquale Maria E
1801 AUGUSTINE CUT-OFF
WILMINGTON
DE
19803
0
1
0
0
EVP & General Counsel
Common Stock
2020-10-09
4
M
0
1423
68.62
A
29754
D
Common Stock
2020-10-09
4
S
0
1423
95.00
D
28331
D
Common Stock
2020-10-12
4
M
0
128
65.36
A
28459
D
Non Qualified Stock Option (right to buy)
68.62
2020-10-09
4
M
0
1423
0.00
D
2028-07-01
Common Stock
1423
10438
D
Incentive Stock Option (right to buy)
65.36
2020-10-12
4
M
0
128
0.00
D
2028-04-09
Common Stock
128
3313
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.
This includes an aggregate of 22,552 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.
Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
Beginning April 9, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
/s/ Maria Pasquale
2020-10-13